Cellular Therapy
Conference Coverage
Novel transplant regimen improves survival in primary immunodeficiency
HOUSTON – Allo-HCT following a novel reduced-intensity conditioning regimen was largely successful in an NIH study of adults and children with...
Conference Coverage
Ixazomib targets treatment failure in chronic GVHD
HOUSTON – Most patients in the phase 2 trial had severe chronic graft-versus-host disease and most had received three or more prior lines of...
Feature
Barriers to CAR T use in the spotlight at first European meeting
European approvals of CAR T-cell therapy are prompting a closer look at economic issues, outcomes data, and future directions.
From the Journals
CLL, GVHD may raise risk for skin cancer after allo-HCT
The retrospective analysis identifies previously unknown risk factor for skin cancer associated with allogeneic hematopoietic cell transplantation...
Conference Coverage
Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML
HOUSTON – The effect was most pronounced in those with high pFLT3 inhibition on plasma inhibitor activity assay.
Conference Coverage
ZUMA-1 update: Axi-cel responses persist at 2 years
HOUSTON – Median duration of response and overall survival have not yet been reached in the pivotal CAR T-cell therapy trial.
Conference Coverage
Dual-targeted CAR T shows ‘clinical signal’ in NHL
HOUSTON – Due to local manufacturing of the CAR T-cell therapy, most patients were able to receive fresh, rather than cryopreserved, product.
Conference Coverage
AlloBMT should be option for older adults with hematologic malignancies
HOUSTON – Allogeneic BMT should not be denied in older adults with hematologic malignancies based on age alone.
Conference Coverage
MRD negativity linked to survival in MM after auto-HCT
HOUSTON – MRD-negative status was prognostic for improved progression-free survival at all time points measured after transplant.
Conference Coverage
Anti-GM-CSF antibody reduced CAR T-cell toxicity
HOUSTON – An early study shows the potential of lenzilumab to reduce CAR T-cell toxicity.
Conference Coverage
Treosulfan may become standard in allo-HCT for AML/MDS
HOUSTON – A treosulfan-based myeloablative conditioning regimen was noninferior to the reduced intensity busulfan-based regimen in event-free...